Skip to main content

Table 2 Patient demographic and clinical characteristics in the 250-patient subset

From: Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States

 

All Patients

(N = 250)

Apalutamide

(N = 125)

Enzalutamide

(N = 125)

Age at most recent visit, years

 Mean (SD)

70.84 (7.84)

70.41 (8.21)

71.28 (7.45)

 Median (Q1-Q3)

70.0 (66.0–76.0)

70.0 (66.0–76.0)

71.0 (66.0–77.0)

Race, N (%)

 White or Caucasian

180 (72.0)

91 (72.8)

89 (71.2)

 Black or African/Caribbean origin

65 (26.0)

31 (24.8)

34 (27.2)

 Asian

2 (0.8)

0 (0.0)

2 (1.6)

 American Indian/Alaska Native

1 (0.4)

1 (0.8)

0 (0.0)

 Unknown

2 (0.8)

2 (1.6)

0 (0.0)

Healthcare coverage at most recent visit, N (%)

 Medicaid

28 (11.2)

15 (12.0)

13 (10.4)

 Medicare

186 (74.4)

92 (73.6)

94 (75.2)

 Medigap

5 (2.0)

3 (2.4)

2 (1.6)

 Private

24 (9.6)

10 (8.0)

14 (11.2)

 Traditional fee-for-service

5 (2.0)

3 (2.4)

2 (1.6)

 Health maintenance organization

9 (3.6)

2 (1.6)

7 (5.6)

 Preferred provider organization

27 (10.8)

18 (14.4)

9 (7.2)

 Veterans Affairs

2 (0.8)

0 (0.0)

2 (1.6)

Body mass index at most recent visit

 Mean (SD)

27.47 (3.90)

27.46 (3.76)

27.47 (4.05)

 Median (Q1-Q3)

26.8 (25.0–28.9)

27.0 (25.3–28.8)

26.8 (24.8–29.0)

Charlson Comorbidity Index, N (%)a

 0

162 (64.8)

85 (68.0)

77 (61.6)

 1

60 (24.0)

27 (21.6)

33 (26.4)

 2+

28 (11.2)

13 (10.4)

15 (12.0)

ECOG score at nmCRPC diagnosis, N (%)

 0

83 (33.2)

34 (27.2)

49 (39.2)

 1

132 (52.8)

71 (56.8)

61 (48.8)

 2

25 (10.0)

11 (8.8)

14 (11.2)

 3+

2 (0.8)

2 (1.6)

0 (0.0)

 Unknown

8 (3.2)

7 (5.6)

1 (0.8)

Gleason score at nmCRPC diagnosis, N (%)

 2 to 6

28 (11.2)

14 (11.2)

14 (11.2)

 7

87 (34.8)

44 (35.2)

43 (34.4)

 8 to 10

94 (37.6)

47 (37.6)

47 (37.6)

 Unknown

41 (16.4)

20 (16.0)

21 (16.8)

PSA at nmCRPC diagnosis (ng/mL)

 N

241

118

123

 Mean (SD)

23.21 (44.15)

20.99 (24.91)

25.35 (56.84)

 Median (Q1-Q3)

12.0 (6.7–26.0)

13.0 (7.0–28.0)

11.0 (6.5–22.4)

  1. Abbreviations: ECOG Eastern Cooperative Oncology Group; Q1-Q3, Range between the first quartile (Q1) and third quartile (Q3); nmCRPC non-metastatic castrate-resistant prostate cancer; PSA Prostate specific antigen; SD, Standard deviation
  2. aCharlson Comorbidity Index was calculated using patient comorbidities present from nmCRPC diagnosis through the end of the study period